



General Assembly

February Session, 2002

Raised Bill No. 528

LCO No. 1493

Referred to Committee on Public Health

Introduced by:
(PH)

**AN ACT CONCERNING COLLABORATIVE PRACTICE BETWEEN
PHYSICIANS AND PHARMACISTS.**

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective October 1, 2002*) (a) One or more
2 pharmacists licensed under chapter 400j of the general statutes, who
3 are determined eligible in accordance with subsection (c) of this
4 section, may enter into a written protocol-based collaborative drug
5 therapy management agreement with one or more physicians licensed
6 under chapter 370 of the general statutes to manage the drug therapy
7 of individual patients in a hospital licensed under chapter 368v of the
8 general statutes in accordance with subsections (b) to (e), inclusive, of
9 this section and subject to the approval of the hospital. Each patient's
10 collaborative drug therapy management shall be governed by a
11 written protocol specific to that patient established by the treating
12 physician in consultation with the pharmacist.

13 (b) A collaborative drug therapy management agreement may
14 authorize a pharmacist to implement, modify or discontinue a drug

15 therapy that has been prescribed for a patient, order associated
16 laboratory tests and administer drugs, all in accordance with a patient
17 specific written protocol. In instances where drug therapy is
18 discontinued, the pharmacist shall notify the treating physician of such
19 discontinuance no later than twenty-four hours from the time of such
20 discontinuance. Each protocol developed, pursuant to the collaborative
21 drug therapy management agreement, shall contain detailed direction
22 concerning the actions that the pharmacists may perform for that
23 patient. The protocol shall include, but need not be limited to, (1) the
24 specific drug or drugs to be managed by the pharmacist, (2) the terms
25 and conditions under which drug therapy may be implemented,
26 modified or discontinued, (3) the conditions and events upon which
27 the pharmacist is required to notify the physician, and (4) the
28 laboratory tests that may be ordered. All activities performed by the
29 pharmacist in conjunction with the protocol shall be documented in
30 the patient's medical record. The pharmacists shall report at least every
31 thirty days to the physician regarding the patient's drug therapy
32 management. The collaborative drug therapy management agreement
33 and protocols shall be available for inspection by the Departments of
34 Public Health and Consumer Protection. A copy of the protocol shall
35 be filed in the patient's medical record.

36 (c) A pharmacist shall be responsible for demonstrating, in
37 accordance with this subsection, the competence necessary for
38 participation in each drug therapy management agreement into which
39 such pharmacist enters. The pharmacist's competency shall be
40 determined by the hospital for which the pharmacist is employed or
41 the hospital that has contracted for the services of the pharmacist. A
42 copy of the criteria upon which the hospital determines competency
43 shall be filed with the Commission of Pharmacy.

44 (d) The Commissioner of Public Health, in consultation with the
45 Commissioner of Consumer Protection, may adopt regulations in
46 accordance with chapter 54 of the general statutes, concerning the
47 minimum content of the collaborative drug therapy management

48 agreement and the written protocol and as otherwise necessary to
49 carry out the purpose of this section.

This act shall take effect as follows:	
Section 1	<i>October 1, 2002</i>

Statement of Purpose:

To establish a collaborative practice between physicians and pharmacists.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]